U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008053) titled 'BR Combined With OR in Treatment-naive Marginal Zone Lymphoma' on May 18.
Brief Summary: This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of BR (bendamustine and zuberitamab) combined with OR (orelabrutinib and zuberitamab) in treatment-naive patients with marginal zone lymphoma.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Marginal Zone Lymphomas
Intervention:
DRUG: BR+OR
Patients who meet the inclusion criteria will enter the treatment period, which consists of an induction phase followed by a maintenance phase. During the induction treatment period, a c...